ARS Pharmaceuticals Inc (NASDAQ: SPRY)’s stock price has increased by 1.52 compared to its previous closing price of 10.55. However, the company has seen a -6.13% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-19 that Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions
Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?
Company’s 36-month beta value is 0.95.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SPRY is 51.12M, and currently, short sellers hold a 24.76% ratio of that floaft. The average trading volume of SPRY on January 03, 2025 was 1.14M shares.
SPRY’s Market Performance
SPRY stock saw a decrease of -6.13% in the past week, with a monthly decline of -19.59% and a quarterly a decrease of -25.88%. The volatility ratio for the week is 6.09%, and the volatility levels for the last 30 days are 6.47% for ARS Pharmaceuticals Inc (SPRY). The simple moving average for the past 20 days is -10.39% for SPRY’s stock, with a -6.93% simple moving average for the past 200 days.
Analysts’ Opinion of SPRY
Raymond James, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $22, previously predicting the price at $18. The rating they have provided for SPRY stocks is “Strong Buy” according to the report published on August 13th, 2024.
Leerink Partners gave a rating of “Outperform” to SPRY, setting the target price at $20 in the report published on August 12th of the previous year.
SPRY Trading at -21.79% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.14% of loss for the given period.
Volatility was left at 6.47%, however, over the last 30 days, the volatility rate increased by 6.09%, as shares sank -21.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.94% lower at present.
During the last 5 trading sessions, SPRY fell by -6.13%, which changed the moving average for the period of 200-days by +17.43% in comparison to the 20-day moving average, which settled at $11.95. In addition, ARS Pharmaceuticals Inc saw 1.52% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Tanimoto Sarina, who sale 100,000 shares at the price of $11.67 back on Dec 17 ’24. After this action, Tanimoto Sarina now owns 1,098,499 shares of ARS Pharmaceuticals Inc, valued at $1,167,100 using the latest closing price.
Lowenthal Richard E, the PRESIDENT AND CEO of ARS Pharmaceuticals Inc, sale 100,000 shares at $11.67 during a trade that took place back on Dec 17 ’24, which means that Lowenthal Richard E is holding 1,098,499 shares at $1,167,100 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -23.84 for the present operating margin
- 0.94 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -19.35. The total capital return value is set at -0.3. Equity return is now at value -22.41, with -21.07 for asset returns.
Currently, EBITDA for the company is -67.45 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 394.52. The receivables turnover for the company is 3.28for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.54.
Conclusion
In a nutshell, ARS Pharmaceuticals Inc (SPRY) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
